Clinical Trials Logo

Clinical Trial Summary

This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.


Clinical Trial Description

This research is a Phase II clinical trial, which means it will test the safety and effectiveness of nivolumab alone (Cohort 1) or in combination with ipilimumab (Cohort 2). Both nivolumab and ipilimumab are antibodies (types of human protein) that work to stop tumor cells from growing and multiplying by immunotherapy. Immunotherapy is trying to have the body's own immune system work against tumor cells. Nivolumab and ipilimumab have both been used in other research studies and information from those other research studies suggests that these interventions may help to stop Meningioma cells from growing. Nivolumab is FDA approved to treat other types of cancers, but the FDA (the U.S. Food and Drug Administration) has not yet approved this intervention for this type of cancer. The FDA has not approved the combination of nivolumab and ipilimumab for your specific disease, but it has been approved for other uses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02648997
Study type Interventional
Source Dana-Farber Cancer Institute
Contact David A Reardon, MD
Phone 617-632-2166
Email david_reardon@dfci.harvard.edu
Status Recruiting
Phase Phase 2
Start date March 2016
Completion date September 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00517959 - SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Phase 3
Completed NCT01880749 - Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas Early Phase 1
Not yet recruiting NCT06466720 - Measuring and Mapping Cognitive Decline After Brain Radiosurgery
Recruiting NCT01655927 - Efficacy of Tranexamic Acid in Brain Tumor Resections Phase 3
Not yet recruiting NCT02939833 - Effects of Scalp Nerve Blocks on Systemic Inflammation N/A